Filtered By:
Source: Cancer Research
Cancer: Colon Cancer
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 53 results found since Jan 2013.
Abstract 5370: The therapeutic strategy using Nek2 siRNA and 5FU for cholangiocarcinoma cell
Conclusion: The therapeutic strategy using Nek2 siRNA and 5FU may be an effective treatment option for cholangiocarcinoma. Further investigation is necessary to clarify the detailed mechanism regulating cell growth and death by a combination of Nek2 siRNA and 5FU.Note: This abstract was not presented at the meeting.Citation Format: Toshio Kokuryo, Yukihiro Yokoyama, Junpei Yamaguchi, Masato Nagino. The therapeutic strategy using Nek2 siRNA and 5FU for cholangiocarcinoma cell. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelph...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Kokuryo, T., Yokoyama, Y., Yamaguchi, J., Nagino, M. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 707: Tumor-targeted delivery of siRNA using stabilized calcium phosphate nanoparticles based on bio-inspired hyaluronic acid conjugate
Conclusion Considering its biocompatibility, transfection efficacy, and tumor targeting capability, this stabilized organic-inorganic hybrid gene delivery platform should be considered a promising candidate carrier for systemic siRNA delivery and targeted cancer therapy.
Citation Format: Min Sang Lee, Jung Eun Lee, Eunkyoung Byun, Nak Won Kim, Haeshin Lee, Ji Hoon Jeong. Tumor-targeted delivery of siRNA using stabilized calcium phosphate nanoparticles based on bio-inspired hyaluronic acid conjugate. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Di...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Lee, M. S., Lee, J. E., Byun, E., Kim, N. W., Lee, H., Jeong, J. H. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 3903: A sub-set of DCLK1+ve colon cancer stem cells (CSCs) survive curcumin induced autophagy, while co-treatment with curcumin +DCLK1-siRNA eliminates CSCs: Role of long and short isofoms of DCLK1
Conclusion. Our studies strongly suggest that, 1) DCLK1 represents a functional protein for colon cancers, 2) combination of curcumin+DCLK1-siRNA may target and eradicate colon cancer stem cells., and 3) identifying small molecules that inhibit expression of S-isoform may allow to specifically target cancer stem cells, while sparing normal stem cells for cancer treatment purposes.
This work was supported by NIH Granst to PS (R01CA09795909 and RO1CA0975909-S1).
Citation Format: Shubhashish Sarkar, Malaney O'Connell, Carla, Kantara, Pomila Singh. A sub-set of DCLK1+ve colon cancer stem cells (CSCs) survive curcumin induced a...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Sarkar, S., O'Connell, M., Kantara, C., Singh, P. Tags: Tumor Biology Source Type: research
Abstract 2958: Discovering therapeutic epigenetic targets using whole genome siRNA screening
Conclusions: A whole genome siRNA screen in combination with the DNMT inhibitor decitabine identified many new target genes that might be epigenetic regulators and potential targets for drug development.Citation Format: Yasuyuki Okamoto, Woonbok Chung, Judith Garriga, Jaroslav Jelinek, Jean-Pierre J. Issa. Discovering therapeutic epigenetic targets using whole genome siRNA screening. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2958. doi:10.1158/1538-7445.AM2015-2958
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Okamoto, Y., Chung, W., Garriga, J., Jelinek, J., Issa, J.-P. J. Tags: Molecular and Cellular Biology Source Type: research
Abstract 3373: Identification of inflammation-related genes that regulate tumor-associated stemness using high-throughput siRNA screening
Cancer associated stem cells (CSCs) are considered to be responsible for tumor recurrence, metastasis as well as chemoresistance. These properties of tumor associated stemness are maintained by specialized microenvironment, including inflammation which is a key component of the tumor microenvironment. To study the relationship between inflammation and stemness of CSCs, here, we established a robust high-throughput RNAi screen platform for a global survey of inflammation-related genes affecting CSCs identity via alteration of Oct4 expression. Consequently, we found 72 novel genes from 1027 inflammation-related genes which c...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Xie, J., He, H., Chen, C., Bai, L., Wang, W., Liu, Y., Guo, J., Wu, P., Xiang, R., Luo, Y. Tags: Tumor Biology Source Type: research
Effects of DCLK1-siRNA{+/-}Curcumin on Cancer Stem Cells
Curcumin is known to induce apoptosis of cancer cells by different mechanisms, but its effects on cancer stem cells (CSC) have been less investigated. Here, we report that curcumin promotes the survival of DCLK1-positive colon CSCs, potentially confounding application of its anticancer properties. At optimal concentrations, curcumin greatly reduced expression levels of stem cell markers (DCLK1/CD44/ALDHA1/Lgr5/Nanog) in three-dimensional spheroid cultures and tumor xenografts derived from colon cancer cells. However, curcumin unexpectedly induced proliferation and autophagic survival of a subset of DCLK1-positive CSCs. Sph...
Source: Cancer Research - April 30, 2014 Category: Cancer & Oncology Authors: Kantara, C., O'Connell, M., Sarkar, S., Moya, S., Ullrich, R., Singh, P. Tags: Prevention and Epidemiology Source Type: research
Abstract 373: An siRNA screen identifies CHD4 as a target for epigenetic therapy
In this study, we used an unbiased screen to investigate therapeutic targets which might be effective combination with DNMT inhibitors in reactivating hypermethylated genes. Methods: We screened an siRNA library targeting 188 gene predicted as epigenetic regulators using colon cancer cells that harbor a GFP locus stably integrated and silenced by a hypermethylated cytomegalovirus (CMV) promoter. GFP-positive cell percentages were measured using Guava EasyCyte Plus flow analyzer software. For genome wide gene expression analysis, affymetrix microarrays were performed. DNA methylation status was evaluated by pyrosequencing a...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Okamoto, Y., Yamazaki, J., Sato, T., Cesaroni, M., Chung, W., Garriga, J., Jelinek, J., Katz, R. A., Issa, J.-P. Tags: Molecular and Cellular Biology Source Type: research
Abstract 509: MicroRNA-140 suppresses the migration and invasion of colorectal cancer cell possibly through targeting Smad3
Conclusions miR-140 directly targets Smad3 in the post-transcriptional level. miR-140 suppresses the migrating and invasive potentials of CRC cell, possibly through down-regulating Smad3. The findings of this study suggest that miR-140 may have a unique potential as a possible biomarker candidate for tumor metastasis diagnosis and therapy.[Keywords] Colon neoplasms; microRNA-140; SMAD family member 3; Cell migration; Cell invasionCitation Format: Bo Song, Wenyue Zhao, Lianhong Li. MicroRNA-140 suppresses the migration and invasion of colorectal cancer cell possibly through targeting Smad3. [abstract]. In: Proceedings of th...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Song, B., Zhao, W., Li, L. Tags: Tumor Biology Source Type: research
Abstract 779: Osteopontin gene expression is associated with 5-fluorouracil drug resistance in colon cancer
Background: Resistance to chemotherapeutic drugs complicates the treatment of cancer patients. The extracellular matrix protein osteopontin (OPN) plays multiple roles in the proliferation and metastasis of cancer cells. We therefore attempted to determine whether OPN expression correlated with drug resistance. Methods: OPN expression in the HCT 116 colon cancer cell line was inhibited by an OPN-short interfering RNA (siRNA). We determined the cytotoxic effect (IC50) of 5-fluorouracil (5FU) on these cells. Patients with recurrence or colorectal cancer or harbored residual tumor cells were treated with S-1-based chemotherapy...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Nakajima, G., Kuramochi, H., Yamamoto, M., Hayashi, K. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 2730: RNAi knockdown or chemical inhibition of anaphase-promoting complex components is synthetic lethal with HSP90 inhibition
The molecular chaperone heat shock protein 90 (HSP90) maintains the conformation, stability and function of oncogenic client proteins, many of which are mutated or overexpressed. Therefore, HSP90 is an important cancer therapeutic target. To further increase the efficacy of HSP90 inhibitors, combinatorial therapeutic strategies may be beneficial. Here we report an unbiased global screening approach to identify genes that encode potentially druggable proteins that modulate cellular responses to HSP90 inhibition. From the 7,593 genes that were tested, three components of the anaphase-promoting complex (APC/C) were among the ...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Howes, J., Lu, B.-F., Powers, M., Mitsopoulos, C., Al-Lazikani, B., Linardopoulos, S., Clarke, P., Workman, P. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 5382: A breakthrough in application of a drug delivery nanoparticle system for therapy and diagnosis of solid tumor
Conclusion:
Our data suggest that sCA itself, while designed as an in vivo delivery device, can facilitate entrance of low molecular chemicals into tumor cells in vitro and in vivo.
Citation Format: Xin Wu, Hirofumi Yamamoto, Mamoru Uemura, Taishi Hata, Junichi Nishimura, Ichiro Takemasa, Tsunekazu Mizushima, Yuichiro Doki, Masaki Mori. A breakthrough in application of a drug delivery nanoparticle system for therapy and diagnosis of solid tumor. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Wu, X., Yamamoto, H., Uemura, M., Hata, T., Nishimura, J., Takemasa, I., Mizushima, T., Doki, Y., Mori, M. Tags: Cancer Chemistry Source Type: research
Abstract 120: Runx3 inhibited epithelial to mesenchymal transition promotes motility and invasiveness of colon cancer cells through reduction of ROS generation
In this study, we investigated the function of Runx3 in human colon cancer cells. The proliferation, migration, and invasion of colon cancer cells in response to using the Runx3 expression vector for various times were investigated using MTT, wound healing, and Matrigel invasion assay, respectively. The morphologic changes of colon cancer cells through the EMT process were monitored by immunofluorescence staining and Western blot assay for EMT markers Twist and Vimentin. We found that Runx3 overexpressing cell inhibited cell motility and invasiveness in colon cancer, and this process was enhanced by Runx3 siRNA. We observe...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Kim, B. R., Kang, M. H., Kim, J. L., Jang, Y. J., Lee, S. I., Kim, J. S., Oh, S. C. Tags: Tumor Biology Source Type: research
Abstract 5455: Resistance to a MEK inhibitor (AZD6244): Its association with increased expression of transcription factor 4
The important role of Ras/Raf/MEK/ERK pathway in carcinogenesis has led to clinical development of MEK inhibitors for treatment of various cancers. Although recent studies have demonstrated impressive antitumor activities of the agents, many tumors show intrinsic and acquired resistance to MEK inhibitors. We tried to find biomarkers that were associated with intrinsic or acquired resistance to a MEK inhibitor (AZD6244) by public microarray data acquisition and development of AZD6244-resistance cell lines. First, we analyzed a set of genome-wide gene expression profiling data from 6 sensitive and 6 resistant cell lines of v...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Goo, B.-K., Hur, E.-H., Choi, Y., Kim, S.-D., Hwang, J. J., Kim, C.-S., Bae, K. S., Choi, J., Cho, S. Y., Yang, S.-H., Lee, J.-H. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 4360: Validation of phosphodiesterase 10A as a cancer target
Phosphodiesterase 10A (PDE10) is a cAMP and cGMP degrading PDE isozyme that is highly expressed in the brain striatum where it plays an important role in cognition and psychomotor activity. PDE10 inhibitors are being developed for the treatment of schizophrenia and Huntington's disease and are generally well tolerated, likely because of low expression levels in peripheral tissues. We recently reported high levels of PDE10 in tumors and that genetic silencing by siRNA inhibits tumor cell growth with a high degree of selectivity over normal cells (Li et al., Oncogene 2014). These observations suggest that PDE10 may have an u...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Lee, K., Li, N., Chen, X., Zhu, B., Yet, L., Madeira da Silva, L., Russo, S., Keeton, A. B., Boyd, M. R., Piazza, G. A. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 4690: Next-generation screen for integrative subtyping and target discovery for KRAS-mutant cancer
Mutations in the small GTPase, KRAS, are found in ∼140,000 new cases of cancer every year in the United States. This heterogeneous class of cancers manifests primarily as adenocarcinomas of the lung, colon and pancreas. These cancers display a wide spectrum of KRAS-dependency and differentially activate downstream effector signaling. The tumors further diverge in their array of co-occurring secondary mutations, expression signatures and KRAS mutant allele. Ultimately, the sole trait these cancers share in common is an obstinate resistance to chemo- and targeted-therapies, making identification of effective treatments an ...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Yuan, T. L., Bagni, R., Yi, M., Amzallag, A., Afghani, S., Beam, K., Burgan, W., Fer, N., Garvey, L., Smith, B., Waters, A., Stephens, R., Benes, C., McCormick, F. Tags: Experimental and Molecular Therapeutics Source Type: research
